SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Axel S Merseburger; Andrea B Apolo; Simon Chowdhury; Noah M Hahn; Matthew D Galsky; Matthew I Milowsky; Daniel Petrylak; Tom Powles; David I Quinn; Jonathan E Rosenberg; Arlene Siefker-Radtke; Guru Sonpavde; Cora N Sternberg

doi:10.1007/s00345-018-2486-1

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.

Authors

Affiliations

¹ Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.
² Center for Cancer Research, National Cancer Institute, NIH Maryland, Bethesda, USA.
³ Guy's and St, Thomas' Hospital, Great Maze Pond, London, UK.
⁴ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
⁵ Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
⁶ Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
⁷ Yale Cancer Center, New Haven, CT, USA.
⁸ Barts Cancer Institute, London, USA.
⁹ Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹⁰ Memorial Sloan Kettering Cancer Center, New York, USA.
¹¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Medical Oncology, Bladder Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA.
¹³ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. cnsternberg@corasternberg.com.

Abstract

The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

Keywords: Bladder cancer; Checkpoint inhibitors; Chemotherapy immunotherapy; Urothelial cancer.

Publication types

Practice Guideline
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Carcinoma, Transitional Cell / drug therapy*
Carcinoma, Transitional Cell / secondary
Cisplatin / administration & dosage
Cisplatin / therapeutic use
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Doxorubicin / therapeutic use
Gemcitabine
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Methotrexate / therapeutic use
Nivolumab / therapeutic use
Paclitaxel / administration & dosage
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / pathology
Vinblastine / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Deoxycytidine
durvalumab
Nivolumab
atezolizumab
Vinblastine
Doxorubicin
Carboplatin
pembrolizumab
avelumab
Paclitaxel
Cisplatin
Methotrexate
Gemcitabine

Supplementary concepts

M-VAC protocol

Grants and funding

P30 CA014089/CA/NCI NIH HHS/United States